Alamar Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Proteomics is at an inflection point, with multiplex testing and high sensitivity enabling new diagnostic and research applications. The platform's unique combination of performance pillars, rapid product expansion, and strong financial growth position it to capture significant market share as it pursues FDA clearance and expands into new disease areas.
-
Q2 2026 revenue grew 82% year-over-year to $29.4 million, driven by strong consumables demand and platform adoption, with gross margin reaching 60%. Full-year revenue is projected at $116–$120 million, and the company remains well-capitalized post-IPO to support growth and R&D expansion.
-
A precision proteomics platform launched in 2024 has achieved rapid adoption, especially in neurology and Alzheimer's research, with strong revenue growth and industry-leading sales efficiency. Strategic priorities include expanding content, commercial reach, and moving toward clinical diagnostics, with FDA submission expected next year.